STUDY OBJECTIVE: To identify whether baseline demographic factors or subjective sleep variables are associated with the outcomes following treatment with eszopiclone using data from a recent randomized controlled trial of 78 Japanese subjects with insomnia who were treated with 2 mg eszopiclone per day. METHODS: We performed a post hoc analysis of factors including sleep latency (SL), wake time after sleep onset (WASO) (both assessed via sleep diaries), and several demographic variables. Subjects with a SL or WASO > 30 min at baseline and with evaluable SL/WASO data at Week 4 were included in SL and WASO remitter analyses, respectively; those with a SL or WASO ≤ 30 min at Week 4 were defined as SL or WASO remitters, respectively. Threshold baseline SL and WASO values for identification of remitters were determined. RESULTS: No relationships between subjectively assessed therapeutic outcomes and demographic factors were identified. Patients with shorter SL and lower WASO values at baseline showed better outcomes following treatment with eszopiclone in terms of SL and WASO changes, respectively. Baseline SL of 75 min and baseline WASO of 80 min were selected as arbitrary cutoff values for determination of SL and WASO remitters/non-remitters, respectively. CONCLUSION: These findings may help clinicians to predict their patients' outcomes in response to standard doses of eszopiclone in clinical practice.
RCT Entities:
STUDY OBJECTIVE: To identify whether baseline demographic factors or subjective sleep variables are associated with the outcomes following treatment with eszopiclone using data from a recent randomized controlled trial of 78 Japanese subjects with insomnia who were treated with 2 mg eszopiclone per day. METHODS: We performed a post hoc analysis of factors including sleep latency (SL), wake time after sleep onset (WASO) (both assessed via sleep diaries), and several demographic variables. Subjects with a SL or WASO > 30 min at baseline and with evaluable SL/WASO data at Week 4 were included in SL and WASO remitter analyses, respectively; those with a SL or WASO ≤ 30 min at Week 4 were defined as SL or WASO remitters, respectively. Threshold baseline SL and WASO values for identification of remitters were determined. RESULTS: No relationships between subjectively assessed therapeutic outcomes and demographic factors were identified. Patients with shorter SL and lower WASO values at baseline showed better outcomes following treatment with eszopiclone in terms of SL and WASO changes, respectively. Baseline SL of 75 min and baseline WASO of 80 min were selected as arbitrary cutoff values for determination of SL and WASO remitters/non-remitters, respectively. CONCLUSION: These findings may help clinicians to predict their patients' outcomes in response to standard doses of eszopiclone in clinical practice.
Authors: Daniel J Foley; Michael V Vitiello; Donald L Bliwise; Sonia Ancoli-Israel; Andrew A Monjan; James K Walsh Journal: Am J Geriatr Psychiatry Date: 2007-04 Impact factor: 4.105
Authors: Thomas Roth; Janet M Price; David A Amato; Robert P Rubens; James M Roach; Thomas J Schnitzer Journal: Prim Care Companion J Clin Psychiatry Date: 2009
Authors: Martin Scharf; Milton Erman; Russell Rosenberg; David Seiden; W Vaughn McCall; David Amato; Thomas C Wessel Journal: Sleep Date: 2005-06 Impact factor: 5.849
Authors: Jack D Edinger; Simon Beaulieu-Bonneau; Hans Ivers; Bernard Guay; Lynda Bélanger; Bryan Simmons; Charles M Morin Journal: Sleep Date: 2022-01-11 Impact factor: 5.849